Patents by Inventor Prakash S. Nagarkatti

Prakash S. Nagarkatti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120302646
    Abstract: Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind CB1 are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has not been studied as extensively as ?9-tetrahydrocannabinol (THC). The present disclosure reports the immunosuppressive properties of CBD and demonstrates that CBD induces apoptosis in thymocytes and splenocytes and inhibits the proliferative responsiveness of T and B cells. This indicates that CB2 selective agonists, devoid of psychotropic effect, may serve as novel anti-inflammatory/immunosuppressive agents.
    Type: Application
    Filed: July 31, 2012
    Publication date: November 29, 2012
    Applicant: University of South Carolina
    Inventors: Prakash S. Nagarkatti, Mitzi Nagarkatti
  • Patent number: 8242178
    Abstract: Methods of treating autoimmune hepatitis are provided. The methods include injecting cannabidiol into the subject, where the cannabidiol is synthetic cannabidiol or natural cannabidiol isolated from other natural cannabinoids.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: August 14, 2012
    Assignee: University of South Carolina
    Inventors: Prakash S. Nagarkatti, Mitzi Nagarkatti
  • Publication number: 20090005461
    Abstract: Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has not been studied as extensively as ?9-tetrahydrocannabinol (THC). The present disclosure reports the immunosuppressive properties of CBD and demonstrates that CBD induces apoptosis in thymocytes and splenocytes and inhibits the proliferative responsiveness of T and B cells. This indicates that CB2 selective agonists, devoid of psychotropic effect, may serve as novel anti-inflammatory/immunosuppressive agents.
    Type: Application
    Filed: June 18, 2008
    Publication date: January 1, 2009
    Applicant: University of South Carolina
    Inventors: Prakash S. Nagarkatti, Mitzi Nagarkatti